BOTANICAL EFFICACY STUDIES: "NEEDLESS IMPEDIMENTS" SHOULD BE REMOVED
This article was originally published in The Tan Sheet
Executive Summary
BOTANICAL EFFICACY STUDIES: "NEEDLESS IMPEDIMENTS" SHOULD BE REMOVED, FDA Office of Drug Evaluation I Director Robert Temple, MD, told a Dec. 14-16 conference on botanicals sponsored by FDA and the Office of Alternative Medicine. "What I want FDA to do is put no needless impediments in the way of doing those trials," Temple said. "We are now seeing a small kernel of people who actually want to do controlled trials...and I'd be upset if we were doing anything to discourage that."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning